<DOC>
	<DOCNO>NCT01962792</DOCNO>
	<brief_summary>Phase 1 open-label study . The dose escalation portion study design establish MTD ibrutinib combination carfilzomib without dexamethasone . Phase 2b open-label , multicenter study design evaluate overall response rate ibrutinib administer combination carfilzomib dexamethasone .</brief_summary>
	<brief_title>Study Bruton 's Tyrosine Kinase Inhibitor Combination With Carfilzomib ( Kyprolis™ ) Subjects With Relapsed Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description>Bruton 's tyrosine kinase ( Btk ) enzyme present hematopoietic cell T cell necessary downstream signal transduction various hematopoietic receptor include B cell receptor well Fc , chemokine , adhesion receptor , crucial B cell development osteoclastogenesis . Although down-regulated normal plasma cell , Btk highly express malignant cell many myeloma patient cell line . PCI-32765 potent specific inhibitor Btk currently Phase 2 3 clinical trial . The current study design intend determine safety efficacy PCI-32765 combination carfilzomib ( Kyprolis™ ) without dexamethasone subject relapse relapsed refractory multiple myeloma ( MM ) .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Measurable disease MM define least ONE following : 1 . Serum monoclonal protein ( SPEP ) ≥1 g/dL 2 . Urine Mprotein ≥200 mg/24 hrs 3 . Serum free light chain ( SFLC ) : involve FLC ≥10 mg/dL ( ≥100 mg/L ) AND abnormal kappa lambda serum free light chain ratio Relapsed relapsed refractory MM receive least 2 previous therapy , include immunomodulator bortezomib either response document disease progression ( accord IMWG criterion ) recent treatment regimen Adequate hematologic , hepatic , renal function ECOG performance status 02 Inclusion Criteria Phase 2 Substudy Cohort : Must meet inclusion criterion define main study addition follow criterion must meet : Subject must receive regimen contain carfilzomib combination dexamethasone recent line therapy : 1 . Achieved less partial response ( &lt; PR ) follow least 4 cycle without evidence progression disease ( PD ) . OR 2 . Disease progression follow initial confirm response MR good combination ( accord IMWG response criterion ) . Subject must primary refractory disease Plasma cell leukemia , primary amyloidosis POEMS syndrome Unable swallow capsule disease significantly affect gastrointestinal function Requires anticoagulation warfarin vitamin K antagonist Requires treatment strong CYP3A inhibitor Exclusion Criteria Phase 2 Substudy Cohort : Must meet exclusion criterion define main study except exclusion criterion `` Subject must primary refractory disease '' relate prior carfilzomib</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>PCI-32765</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Relapsed Refractory Multiple Myeloma</keyword>
	<keyword>Bruton 's Tyrosine Kinase</keyword>
	<keyword>Carfilzomib</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Ibrutinib</keyword>
</DOC>